Evidence map›Paper›PMID 26823819›Full record

ArticleInternational journal of clinical and experimental pathology2015

Prognostic significance of preoperative C-reactive protein: albumin ratio in patients with clear cell renal cell carcinoma.

Zhen Chen, Yingjie Shao, Min Fan, Qianfeng Zhuang, Kun Wang, Wei Cao, Xianlin Xu, Xiaozhou He

Abstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhen ChenDepartment of Urology, The Third Affiliated Hospital of Soochow University Changzhou 213003, P. R. China.
Yingjie ShaoDepartment of Radiation Oncology, The Third Affiliated Hospital of Soochow University Changzhou 213003, P. R. China.
Min FanDepartment of Urology, The Third Affiliated Hospital of Soochow University Changzhou 213003, P. R. China.
Qianfeng ZhuangDepartment of Urology, The Third Affiliated Hospital of Soochow University Changzhou 213003, P. R. China.
Kun WangDepartment of Urology, The Third Affiliated Hospital of Soochow University Changzhou 213003, P. R. China.
Wei CaoDepartment of Urology, The Third Affiliated Hospital of Soochow University Changzhou 213003, P. R. China.
Xianlin XuDepartment of Urology, The Third Affiliated Hospital of Soochow University Changzhou 213003, P. R. China.
Xiaozhou HeDepartment of Urology, The Third Affiliated Hospital of Soochow University Changzhou 213003, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We undertook a retrospective analysis to evaluate the C-reactive protein/albumin (CRP/Alb) ratio for its prognostic value in patients with clear cell renal cell carcinoma (CCRCC). The study comprised 406 CCRCC patients undergoing nephrectomy between 2003 and 2012 in our hospital. The correlations among the pretreatment CRP/Alb ratio, clinicopathological parameters, and overall survival (OS) were evaluated. An elevated CRP/Alb ratio was associated with older age at surgery (P=0.007), more advanced TNM stage (P<0.001), more presence of tumor necrosis (P<0.001) and lymphovascular invasion (P<0.001), lower concentration of hemoglobin (P<0.001) and calcium (P=0.005), and shorter OS (P<0.001). The multivariate analysis confirmed that the CRP/Alb ratio independently predicted the OS of patients with CCRCC (P<0.001), the Glasgow Prognostic Score (GPS) (P=0.001) and modified GPS (mGPS) (P=0.019) were independent prognostic factors also. At last, we evaluated the prognostic value of the CRP/Alb ratio compared with the similar inflammation-based prognostic scores GPS and mGPS using the area under the curve (AUC). Although the differences were not statistically significant, the AUC value of the CRP/Alb ratio (continuous, categorical) was higher compared with the GPS and mGPS, except that the AUC value for the CRP/Alb ratio (categorical) at 3 years was lower than that for the GPS. The CRP/Alb ratio could take the place of the GPS and mGPS in terms of predicting prognosis in CCRCC.

Indexed as

AdultAgedAged, 80 and overArea Under CurveBiomarkers, TumorCarcinoma, Renal CellC-Reactive ProteinFemaleHumansInflammationKaplan-Meier EstimateKidney NeoplasmsMaleMiddle AgedPrognosisProportional Hazards ModelsBiomarkers, TumorC-Reactive ProteinSerum AlbuminalbuminClear cell renal cell carcinomaC-reactive proteinprognosis

Identifiers

PMID26823819
PMCPMC4713605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.